Last update 01 Nov 2024

eotaxin-2

Last update 01 Nov 2024

Basic Info

Synonyms

C-C motif chemokine 24, C-C motif chemokine ligand 24, CCL24

+ [12]

Introduction

Chemotactic for resting T-lymphocytes, and eosinophils (PubMed:9104803, PubMed:9365122). Has lower chemotactic activity for neutrophils but none for monocytes and activated lymphocytes (PubMed:9104803, PubMed:9365122). Is a strong suppressor of colony formation by a multipotential hematopoietic progenitor cell line (PubMed:9104803, PubMed:9365122). Binds to CCR3 (PubMed:9104803, PubMed:9365122).

Drugs associated with eotaxin-2

Nebokitug

Target

eotaxin-2

Mechanism

eotaxin-2 inhibitors

Active Org.

Royal Free Hospital Medical School [+4]

Originator Org.

Chemomab Ltd.

Active Indication

Scleroderma, Systemic [+1]

Inactive Indication

Nonalcoholic Steatohepatitis

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with eotaxin-2

NCT06210945 / SuspendedPhase 2

A Phase 2, Multicenter, Randomized, Double-Blind, Proof of Biology Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis

This study is designed to assess the safety and tolerability of the anti-human CCL24 monoclonal antibody CM-101 in adult patients with systemic sclerosis (SSc). Approximately 45 patients at approximately 40 sites will be randomized in a 2:1 ratio to receive either 10 mg/kg CM-101 or placebo.

Start Date01 Sep 2024

Sponsor / Collaborator

Chemomab Ltd.

NCT05824156 / CompletedPhase 2

Phase 2A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of CM-101 in Patients With Non-Alcoholic Steatohepatitis (NASH)

This phase 2a study is a multi-center, double-blind randomized, placebo-controlled study. The study is designed to determine the safety and tolerability of the anti-human CCL24 monoclonal antibody CM-101 in adult patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) patients with stage 1c, 2 or 3 fibrosis. The patients will be randomized to 1 of 2 treatment groups: 5 mg/kg CM-101 or placebo.

Start Date24 Feb 2021

Sponsor / Collaborator

Chemomab Ltd.

NCT04595825 / Active, not recruitingPhase 2

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Safety and Efficacy of CM-101 in Subjects With Primary Sclerosing Cholangitis (The SPRING Study)

This study is designed to assess the safety, tolerability and activity of the anti-human CCL24 monoclonal antibody CM-101 in adult subjects with Primary Sclerosing Cholangitis (PSC). At least 68 subjects at approximately 50 sites will be randomized to receive either CM-101 at doses of 10 mg/kg or 20 mg/kg or matching placebo.

Start Date01 Oct 2020

Sponsor / Collaborator

Chemomab Ltd.

100 Clinical Results associated with eotaxin-2

100 Translational Medicine associated with eotaxin-2

0 Patents (Medical) associated with eotaxin-2

777

Literatures (Medical) associated with eotaxin-2

01 Dec 2024·Veterinary Immunology and Immunopathology

Expression of key immune genes in polarized porcine monocyte-derived macrophage subsets

Article

Author: Graham, Simon P ; Columbano, Nicolò ; Dei Giudici, Silvia ; Graham, Simon P. ; Dell'Anno, Filippo ; Dell’Anno, Filippo ; Franzoni, Giulia ; Razzuoli, Elisabetta ; De Ciucis, Chiara G ; De Ciucis, Chiara G. ; Zinellu, Susanna ; Giudici, Silvia Dei ; Fruscione, Floriana ; Mura, Lorena

Swine are considered one of the most relevant large animal biomedical models since they share many immunological similarities with humans. Despite that, macrophage polarization has not comprehensively investigated in pigs. In this study, porcine monocyte-derived macrophages (moMΦ) were untreated or stimulated with IFN-γ + LPS (classical activation), or by different M2 polarizing stimuli: IL-4, IL-10, TGF-β, or dexamethasone. Expression of key cytokine genes (IL1B2, IL33, IL19, IL22, IL26, CCL17, CCL24, IFNA, IFNB) in macrophage subsets were investigated over time. Expression of the genes encoding the two main enzymes of the arginine pathway (ARG1, NOS2), and molecules related to alternative macrophage polarization in human and mice (MMP9, MRC1, FIZZ1, VEGFA) were also assessed. Stimulation with IFN-γ + LPS triggered up-regulation of IL1B2, IFNB, NOS2, whereas IL-4 triggered upregulation of CCL17, CCL24, CXCR2, and ARG1 expression. IL19 and IL22 expression was enhanced by stimulation with IFN-γ + LPS or TGF-β, but not IL-4, IL-10, or dexamethasone. Our data highlighted some peculiarities in swine, such as induced expression of IL33 after stimulation with IFN-γ + LPS, and no up-regulation of FIZZ1, VEGFA or MMP9 after exposure to any of the M2 polarizing stimuli. A better understanding of porcine macrophage polarization could benefit translational studies using this large animal model.

01 Nov 2024·Otolaryngology–Head and Neck Surgery

Inflammatory Profile of Chronic Rhinosinusitis With Nasal Polyp Patients in Brazil: Multicenter Study

Article

Author: Miyake, Marcel M. ; Fernandes, Atilio M. ; Lopes, Natália M. D. ; Murata, Juliana ; Tamashiro, Edwin ; Almeida, Laiana do C. ; Sakano, Eulália ; Tepedino, Miguel S. ; Lessa, Marcus M. ; Freire, Gustavo S. M. ; Batista Murashima, Adriana de A. ; Gregorio, Luciano L. ; Nakanishi, Marcio ; Meotti, Camila D. ; dos Santos, Marco C. J. ; Roithmann, Renato ; Anselmo‐Lima, Wilma ; da Silva, Lilian E. C. M. ; Valera, Fabiana C. P. ; Toro, Mariana D. C. ; de Mendonça Pilan, Renata R. ; Camargo, Leandro A. ; Kosugi, Eduardo M. ; Fornazieri, Marco A. ; Arruda, Eurico ; Romano, Fabrizio R. ; Vianna, Pedro M. ; Moras, Luis L. ; Redeker, Nicole ; Dolci, Ricardo L. L. ; Garcia, Denny M. ; Piltcher, Otávio B. ; Voegels, Richard L. ; Bezerra, Thiago F. P. ; Avelino, Melissa A. G.

AbstractObjectivesTo determine the inflammatory profile of CRSwNP in Brazil and characterize the subgroups of CRSwNP patients in this population through cluster analysis.Study DesignMulticenter cross‐sectional study involving 15 centers representing different regions of Brazil.Subjects and MethodsClinical data of 166 patients and 80 controls, aged 18 to 70 years old, number of surgeries for CRS, history of asthma and aspirin sensitivity, and Lund‐Mackay scores on CT scans. During nasal endoscopy, we obtained the Lund‐Kennedy scores and collected 2 samples of nasal polyps: one for eosinophil and neutrophil tissue counts and one to quantify different cytokines.Results79.6% of our patients had 10 or more eosinophils/HPF. CRSwNP groups exhibited significantly lower concentrations of TNF‐alpha and significantly higher concentrations of IFN‐gamma, CCL11/Eotaxin, CCL24/Eotaxin‐2/MPIF‐2, and CCL26/Eotaxin‐3 versus the control group (Kruskal‐Wallis test). Comparison between CRSwNP groups (≥10 vs <10 eosinophils/HPF) showed no difference in cytokine concentration (Mann‐Whitney test). Hierarchical clustering and PCA according to cytokine concentrations revealed 2 main Clusters, with a significantly higher concentration of all cytokines in Cluster 1 (n = 35) than in Cluster 2 (n = 121), except IL‐6 and IL‐33 (Mann‐Whitney test). According to ROC curve analysis the best cut‐off to differentiate the 2 clusters was 43 eosinophils/HPF. The group with ≥43 presented a higher prevalence of men and a higher Lund‐Mackay score (Mann‐Whitney test).ConclusionsCRSwNP patients in Brazil present mixed inflammation, with 2 distinct groups (high and low inflammatory pattern) that can be distinguished by tissue eosinophilia of ≥43 eosinophils/HPF cut‐off in nasal polyps.

01 Nov 2024·Cytokine

UFMylation is involved in serum inflammatory cytokines generation and splenic T cell activation induced by lipopolysaccharide

Article

Author: Qiu, Wei ; Su, Ming ; Wang, Sixu ; Liu, Hui ; Yang, Jing ; Liu, Yuyang

UFMylation, a novel ubiquitin-like protein modification system, has been recently found to be activated in inflammation. However, the effects of UFMylation activation on inflammation in vivo remains unclear. In the present study, we generated a UFMylation activated mice using transgenic (TG) techniques. Lipopolysaccharide (LPS) was used to induce systemic inflammation in both TG and non-transgenic (NTG) mice. Serum cytokines were detected using a Mouse Cytokine Array, and the proportions of splenic NK, B and T cells were determined by using flow cytometry. We found that TG mice showed increased serum G-CSF, TNF RII and decreased serum TCA-3, CD30L, bFGF, IL-15 and MIG compared with NTG mice at baseline. Furthermore, serum cytokines in TG mice exhibited different responses to LPS compared to NTG mice. LPS up-regulated serum TNF RII, G-CSF, MCP-5, RANTES, KC, BLC, MIG and down-regulated IL-1b, IL-2, IL-3, IL-4, IL-5, IL-7, IL-10, IL-12p40, IL-15, IL-17, IFN-γ, TCA-3, Eotaxin-2, LIX, MCP-1, TNFα, GM-CSF in NTG mice, whereas LPS up-regulated G-CSF, MCP-5, RANTES, KC, BLC, MIG, ICAM-1, PF4, Eotaxin, CD30L, MIP-1a, TNFRI and down-regulated IL-1b, IL-3, LIX, MCP-1, TNFα, GM-CSF in TG mice. Data from flow cytometry indicated that LPS significantly reduced the percentages of NK and NKT cells in NTG mice, whereas UFMylation activation inhibited LPS-induced NKT cell decrease. The proportions of B cells, total CD4⁺ and total CD8⁺ T cells were comparable between TG and NTG mice in response to LPS treatment, whereas the percentages of CD4⁺CD69⁺ and CD8⁺CD69⁺T cells were lower in TG mice. These findings suggest that UFMylation may alter LPS-induced serum cytokine profile and participate in splenic T cell activation in vivo.

News (Medical) associated with eotaxin-2

30 Oct 2024

·www.globenewswire.com

Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

TEL AVIV, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or the “Company”), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its third quarter 2024 financial results and providing a business update on November 14, 2024, at 7:00 am Eastern Time. Investors who would like to discuss the financial results or business update after the press release has been issued are invited to contact the company at IR@chemomab.com. About Chemomab Therapeutics Ltd. Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a first-in-class dual activity monoclonal antibody that neutralizes CCL24 activity and has demonstrated disease-modifying potential. In clinical and preclinical studies, CM-101 has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of CM-101 in patients. Based on recent promising data from its Phase 2 SPRING trial in the rare liver disease primary sclerosing cholangitis (PSC), the company expects two milestones in early 2025, including FDA feedback on the design of its planned PSC Phase 3 registrational trial and data from the SPRING trial open label extension. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information, visit: chemomab.com. Contact: Media & Investors: Chemomab TherapeuticsBarbara LindheimConsulting Vice PresidentInvestor & Public Relations, Strategic CommunicationsPhone: +1 917-355-9234barbara.lindheim@chemomab.com IR@chemomab.com

Phase 2Clinical ResultFinancial StatementFast TrackOrphan Drug

15 Oct 2024

·www.globenewswire.com

Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024

TEL AVIV, Israel, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that its late breaking abstract discussing the results of the Phase 2 SPRING trial in primary sclerosing cholangitis (PSC) has been selected for an oral presentation at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024. The conference will take place in San Diego, California, November 15 – 19, 2024. Professor Christopher Bowlus, MD, FAASLD, the Lena Valente Professor and Chief of the Division of Gastroenterology and Hepatology at the University of California Davis School of Medicine will give an oral presentation describing data from the double-blinded portion of the Phase 2 SPRING trial assessing CM-101 in individuals with PSC.Title: CM-101 improved fibrosis biomarkers in patients with primary sclerosing cholangitis: The Phase 2 SPRING StudyAuthor: Christopher Bowlus, MDSession: Late Breaking Abstract Parallel Session 1Session Time: November 18, 2024, 2:00pm – 3:30pm PDTPresentation Time: November 18, 2024, 2:45 - 3:00pm PTPublication Number: 5005 Members of the Chemomab senior leadership team will be attending the 2024 AASLD conference. Please reach out to set up a meeting or to learn more about the company. About Chemomab Therapeutics Ltd.Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a dual activity monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of CM-101 in patients. Based on recent promising data from its Phase 2 trial in the rare liver disease primary sclerosing cholangitis (PSC), the company expects two upcoming milestones in early 2025, including FDA feedback on the design of its planned PSC Phase 3 registrational trial. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information, visit www.chemomab.com. Contacts: Media and Investors:Barbara LindheimConsulting Vice President, Investor & Public Relations, Strategic CommunicationsPhone: +1 917-355-9234barbara.lindheim@chemomab.comIR@chemomab.com

Phase 2Fast TrackOrphan DrugClinical Result

01 Oct 2024

·www.globenewswire.com

Chemomab Therapeutics to Present at October 2024 Investor Conferences

TEL AVIV, Israel, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that senior management will participate in two upcoming investor conferences. Chemomab management will meet with investors at the Third Annual ROTH Healthcare Opportunities Conference at the Metropolitan Club in New York City on October 9, 2024, and Chemomab co-founder and Chief Executive Officer Dr. Adi Mor will participate in a fireside chat with senior biotechnology analyst Michael Okunewitch at the Maxim Healthcare Virtual Summit on October 16, 2024 at 9:00 am ET. These conferences are by invitation only. A recording of the Maxim Healthcare Summit fireside chat will be available via a link on the Chemomab investor relations website after the conference completes. Chemomab Participation in Third Annual ROTH Healthcare Opportunities Conference Date:October 9, 2024Time:9:00 am ET - 5:00 pm ETVenue:Metropolitan Club, New York CityFormat:One-on-one meetings with investorsInformation:https://www.meetmax.com/sched/event_111103/conference_home.html Chemomab Participation in 2024 Maxim Healthcare Virtual Summit Date:October 16, 2024Time:9:00 am ETVenue:VirtualFormat:Fireside chat with CEO Dr. Adi MorLink:Recording will be available at investors.chemomab.com post-conference.Information:https://m-vest.com/events/healthcare-10152024 About Chemomab Therapeutics Ltd.Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a dual activity monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of CM-101 in patients. Based on recent promising data from its Phase 2 trial in the rare liver disease primary sclerosing cholangitis (PSC), the company expects two upcoming milestones in early 2025, including FDA feedback on the design of its planned PSC Phase 3 registrational trial. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information, visit www.chemomab.com. Contacts: Media and Investors:Barbara LindheimConsulting Vice President, Investor & Public Relations, Strategic CommunicationsPhone: +1 917-355-9234barbara.lindheim@chemomab.comIR@chemomab.com

Fast TrackPhase 2Clinical ResultOrphan Drug

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

eotaxin-2

Basic Info

Related

Analysis